Machine learning-driven programmed cell death signature for prognosis and drug candidate discovery in diffuse large B-cell lymphoma: Multi-cohort study and experimental validation.

Abstract

Authors

• Bin Luo
• Le Yu
  Tobacco Research Institute, Chinese Academy of Agricultural Sciences, Qingdao, China.
• Wei Zhang
  The First Affiliated Hospital of Nanchang University, Nanchang, China.
• Jiawei Fan
  Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
• Mengdi Wan
  School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau 999078 (or Macau SAR), China.
• Huangming Hong
  Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No.55, Section South Renmin Road, Chengdu, China.
• Yizhun Zhu
  School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau 999078 (or Macau SAR), China; School of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau 999078 (or Macau SAR), China.
• Tongyu Lin
  Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No.55, Section South Renmin Road, Chengdu, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: lintongyu@scszlyy.org.cn.

Keywords

No keywords available for this article.

External Resources